Table 3.

Interventional Characteristics in the Studies Included in This Metaanalysis

StudyDrug-Eluting Stent UseTime for Secondary Procedure, daysMedical TreatmentFollow-up, months
Di Mario et al,29 2004None; all heparin-coated Bx Velocity stents (Cordis Corporation, Cardinal Health)Not specifiedAspirin Clopidogrel or ticlopidine12
Politi et al,30 2010Infarct artery:10 (11.9%) in the culprit artery only group 5 (7.7%) in the multivessel group 6 (9.2%) in the staged multivessel group42.3 ± 22.8Aspirin Statin Clopidogrel for 30 days if bare metal stent or 1 year if drug-eluting stent30 ± 17
Wald et al,24 2013Infarct artery:147 (62.8%) in the multivessel group 135 (58.4%) in the culprit artery only group Non–infarct-related artery: 165 (70.5%) in the multivessel group40Aspirin Clopidogrel, prasugrel, or ticagrelor Statin Beta blocker Angiotensin-converting enzyme inhibitor23
Gershlick et al,25 2015141 (94.0%) in the multivessel group127 (87.0%) in culprit artery only groupNot specifiedAspirin Clopidogrel, prasugrel, or ticagrel or Statin Beta blocker Angiotensin-converting enzyme inhibitor12